Testing repeat doses of a stem cell and virus treatment for glioblastoma that has come back
Official title: Multiple Intracerebral Doses of Neural Stem Cell-Based Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This study tests if giving several doses of a new treatment into the brain is safe.
Read our full plain-language summary
What the trial team says
This phase I trial studies the safety of giving multiple intracerebral doses of NSC-CRAd-S-pk7 to treat patients with glioblastoma at first recurrence. NSC-CRAd-S-pk7 consists of neural stem cells that can target glioblastoma cells and carry a virus, which can kill cancer cells. Giving multiple doses of NSC-CRAd-S-pk7 may kill more tumor cells.
Key facts
- Registry number
- NCT05139056
- Stage of testing
- Phase 1
- Conditions studied
- Currently Only Enrolling Glioblastoma Patients at First Recurrence
Where it is running
This trial lists 4 sites.
-
California
- City of Hope Medical Center (Duarte)
- Standford University (Stanford)
-
Illinois
- Northwestern University (Chicago)
-
North Carolina
- Wake Forest University (Winston-Salem)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.